MRI-Visualized, Dual-Targeting, Combined Tumor Therapy Using Magnetic Graphene-Based Mesoporous Silica

Targeting peptide‐modified magnetic graphene‐based mesoporous silica (MGMSPI) are synthesized, characterized, and developed as a multifunctional theranostic platform. This system exhibits many merits, such as biocompatibility, high near‐infrared photothermal heating, facile magnetic separation, large T2 relaxation rates (r2), and a high doxorubicin (DOX) loading capacity. In vitro and in vivo results demonstrate that DOX‐loaded MGMSPI (MGMSPID) can integrate magnetic resonance imaging, dual‐targeting recognition (magnetic targeting and receptor‐mediated active targeting), and chemo‐photothermal therapy into a single system for a visualized‐synergistic therapy of glioma. In addition, it is observed that the MGMSPID system has heat‐stimulated, pH‐responsive, sustained release properties. All of these characteristics would provide a robust multifunctional theranostic platform for visualized glioma therapy. Visualized‐synergistic targeting therapy: An excellent nanomedicine based on PEGylated and IP‐modified magnetic graphene‐based mesoporous silica is developed for the MRI‐visualized, dual‐targeting, and synergistic chemo‐photothermal glioma therapy. This nanomedicine also exhibits desirable drug release characteristics including heat‐stimulative, pH‐responsive, and sustained release. The multifunctional nanomedicine will be a powerful theranostic platform for cancer therapy.